The UK and US have finalized a landmark bilateral deal that will maintain no import taxes on British medicine exports entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to increase expenditure on medicines through the public health system. This commitment guarantees that duties on these crucial exports will remain at zero for a period of three years.
This deal is in response to previous threats to hike import taxes on patented pharmaceutical products, with figures floated as high as one hundred percent.
"This arrangement with the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes long-overdue balance to American-British drug exports," a release noted.
Commercial Importance
Pharmaceuticals represent one of the Britain's largest goods shipped to the United States, which is easily the primary buyer for large British pharmaceutical firms.
Statistics show that in the 12 months prior to September, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This agreement protects work, stimulates investment and facilitates the UK to become a international leader for medical research," a government official remarked.
Key NHS Changes
The agreement involves several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be capped at 15%. Last year, refunds were more than 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were exacerbated by assertions that US patients were paying a premium for the identical medicines than consumers in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.
